Literature DB >> 15358402

Identifying parents in pharmacy data: a tool for the continuous monitoring of drug exposure to unborn children.

Eric Schirm1, Hilde Tobi, Lolkje T W de Jong-van den Berg.   

Abstract

OBJECTIVE: This study aimed to develop and validate a method for retrospectively identifying parents in pharmacy data during pregnancy. STUDY DESIGN AND
SETTING: The principle of the method was to select all children 0-2 years in pharmacy records, and to consider men/women 15-50 years older with the same address as fathers/mothers.
RESULTS: Applying this method to the records of all 4 pharmacies in 1 town (33,000 inhabitants) resulted in identification of 807 fathers and 765 mothers, corresponding with 68.5% of all fathers, and 64.9% of all mothers from the town. Additionally, the method was applied to one selected pharmacy, resulting in 151 fathers and 170 mothers. Validation criterions, evaluated by pharmacy employees and GPs, disproved one of these fathers (0.7% of all identified fathers) and one mother (0.6%).
CONCLUSION: We conclude that automatic retrospective identification of parents in pharmacy data is feasible in a valid way. The main limitation is that not all parents were found, possibly resulting in selection bias.

Entities:  

Mesh:

Year:  2004        PMID: 15358402     DOI: 10.1016/j.jclinepi.2002.12.001

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  11 in total

1.  Prescribing of NSAIDs and ASA during pregnancy; do we need to be more careful?

Authors:  Fokaline Vroom; Paul B van den Berg; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2008-02       Impact factor: 4.335

2.  Prevalence and patterns of antidepressant drug use during pregnancy.

Authors:  Tessa Ververs; Hans Kaasenbrood; Gerard Visser; Fred Schobben; Lolkje de Jong-van den Berg; Toine Egberts
Journal:  Eur J Clin Pharmacol       Date:  2006-08-08       Impact factor: 2.953

3.  Identifying associations between maternal medication use and birth defects using a case-population approach: an exploratory study on signal detection.

Authors:  Linda de Jonge; Priscilla A Zetstra-van der Woude; H Jens Bos; Lolkje T W de Jong-van den Berg; Marian K Bakker
Journal:  Drug Saf       Date:  2013-11       Impact factor: 5.606

Review 4.  Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 2: Testing the hypotheses.

Authors:  Cynthia M Nijenhuis; Peter G J ter Horst; Nienke van Rein; Bob Wilffert; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

5.  Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.

Authors:  Marian K Bakker; Pieternel Kölling; Paul B van den Berg; Hermien E K de Walle; Lolkje T W de Jong van den Berg
Journal:  Br J Clin Pharmacol       Date:  2007-10-22       Impact factor: 4.335

6.  In utero exposure to antidepressants and the use of drugs for pulmonary diseases in children.

Authors:  P G J ter Horst; H J Bos; L T W de Jong-van de Berg; B Wilffert
Journal:  Eur J Clin Pharmacol       Date:  2012-07-20       Impact factor: 2.953

7.  P-Glycoprotein-Mediated Drug Interactions in Pregnancy and Changes in the Risk of Congenital Anomalies: A Case-Reference Study.

Authors:  Aizati N A Daud; Jorieke E H Bergman; Marian K Bakker; Hao Wang; Wilhelmina S Kerstjens-Frederikse; Hermien E K de Walle; Henk Groen; Jens H J Bos; Eelko Hak; Bob Wilffert
Journal:  Drug Saf       Date:  2015-07       Impact factor: 5.606

8.  Knowledge and attitude regarding pharmacogenetics among formerly pregnant women in the Netherlands and their interest in pharmacogenetic research.

Authors:  Aizati N A Daud; Eefke L Bergsma; Jorieke E H Bergman; Hermien E K De Walle; Wilhelmina S Kerstjens-Frederikse; Bert J Bijker; Eelko Hak; Bob Wilffert
Journal:  BMC Pregnancy Childbirth       Date:  2017-04-14       Impact factor: 3.007

9.  Maternal use of drug substrates of placental transporters and the effect of transporter-mediated drug interactions on the risk of congenital anomalies.

Authors:  Aizati N A Daud; Jorieke E H Bergman; Monika P Oktora; Wilhelmina S Kerstjens-Frederikse; Henk Groen; Jens H Bos; Eelko Hak; Bob Wilffert
Journal:  PLoS One       Date:  2017-03-13       Impact factor: 3.240

10.  Impact of Muscarinic M3 Receptor Antagonism on the Risk of Type 2 Diabetes in Antidepressant-Treated Patients: A Case-Controlled Study.

Authors:  Yen-Hao Tran; Catharina C M Schuiling-Veninga; Jorieke E H Bergman; Henk Groen; Bob Wilffert
Journal:  CNS Drugs       Date:  2017-06       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.